Avadel Pharmaceuticals (AVDL)
(Delayed Data from NSDQ)
$17.81 USD
-0.01 (-0.06%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $17.82 +0.01 (0.06%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth B Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
AVDL 17.81 -0.01(-0.06%)
Will AVDL be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for AVDL based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for AVDL
Here's Why You Should Invest in Avadel (AVDL) Stock Now
Avadel (AVDL) is a Great Momentum Stock: Should You Buy?
AVDL: What are Zacks experts saying now?
Zacks Private Portfolio Services
How Much Upside is Left in Avadel (AVDL)? Wall Street Analysts Think 37.36%
Why Avadel Pharmaceuticals (AVDL) Stock Might be a Great Pick
Will Humana (HUM) Q2 Earnings Beat on Strong Pharmacy Business?
Other News for AVDL
Jazz Pharmaceuticals: Cheap But Complicated
Avadel Pharmaceuticals call buyer realizes 17% same-day gains
Avadel Pharmaceuticals Shifts to Nasdaq, Ends ADR Program
Avadel Pharmaceuticals: A Deep Dive Into Lumryz's Once-Nightly Revolution
Avadel Pharmaceuticals to Present at the 23rd Annual Needham Healthcare Conference